HMG CoA reductase inhibitor (statin) and aortic valve calcium

Lancet

Volumn 359, Issue 9312, 2002, Pages 1125-1126

  Shavelle, David M ^a   Takasu, Junichuro ^b   Budoff, Matthew J ^b   Mao, SongShou ^b   Zhao, Xue Qiao ^a   O'Brien, Kevin D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

AORTA ATHEROSCLEROSIS; AORTA VALVE STENOSIS; ARTERY CALCIFICATION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELECTRON BEAM TOMOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

EID: 0037197017     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08161-8     Document Type: Article

References (5)

1. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis
2. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health study
3. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
4. Coronary artery disease: Improved reproducibility of calcium scoring with an electron-beam CT volumetric method
5. Electron beam computed tomography for the quantification of aortic valvular calcification